^
Association details:
| Biomarker: | SLC3A2-NRG1 fusion |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | seribantumab (MM-121) (HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions
Published date:
03/10/2021
Excerpt:
Seribantumab treatment of H6c7-ATP1B1-NRG1 and H6c7-SLC3A2-NRG1 cells resulted in dose-dependent inhibition of cell growth with IC50 values of 0.05 and 0.2 µM, respectively.
